JP2012529296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012529296A5 JP2012529296A5 JP2012515080A JP2012515080A JP2012529296A5 JP 2012529296 A5 JP2012529296 A5 JP 2012529296A5 JP 2012515080 A JP2012515080 A JP 2012515080A JP 2012515080 A JP2012515080 A JP 2012515080A JP 2012529296 A5 JP2012529296 A5 JP 2012529296A5
- Authority
- JP
- Japan
- Prior art keywords
- xten
- fusion protein
- seq
- sequence
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 63
- 102000037865 fusion proteins Human genes 0.000 claims 63
- 102000018997 Growth Hormone Human genes 0.000 claims 36
- 108010051696 Growth Hormone Proteins 0.000 claims 36
- 239000000122 growth hormone Substances 0.000 claims 36
- 150000007523 nucleic acids Chemical class 0.000 claims 20
- 150000001413 amino acids Chemical group 0.000 claims 19
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 8
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 8
- 230000001225 therapeutic effect Effects 0.000 claims 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 7
- 230000000295 complement effect Effects 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 210000001612 chondrocyte Anatomy 0.000 claims 4
- 230000036470 plasma concentration Effects 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 235000018102 proteins Nutrition 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- 208000037415 AIDS wasting syndrome Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 206010056438 Growth hormone deficiency Diseases 0.000 claims 2
- 206010053759 Growth retardation Diseases 0.000 claims 2
- 208000003577 HIV wasting syndrome Diseases 0.000 claims 2
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 claims 2
- 208000029725 Metabolic bone disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims 2
- 208000026928 Turner syndrome Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 230000036765 blood level Effects 0.000 claims 2
- 230000037182 bone density Effects 0.000 claims 2
- 230000008468 bone growth Effects 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 210000004349 growth plate Anatomy 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 201000006938 muscular dystrophy Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 102100020948 Growth hormone receptor Human genes 0.000 claims 1
- 102000002265 Human Growth Hormone Human genes 0.000 claims 1
- 108010000521 Human Growth Hormone Proteins 0.000 claims 1
- 239000000854 Human Growth Hormone Substances 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 108010068542 Somatotropin Receptors Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000000805 cytoplasm Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18511209P | 2009-06-08 | 2009-06-08 | |
| US61/185,112 | 2009-06-08 | ||
| US23683609P | 2009-08-25 | 2009-08-25 | |
| US61/236,836 | 2009-08-25 | ||
| US28095509P | 2009-11-10 | 2009-11-10 | |
| US61/280,955 | 2009-11-10 | ||
| PCT/US2010/023106 WO2010091122A1 (en) | 2009-02-03 | 2010-02-03 | Extended recombinant polypeptides and compositions comprising same |
| US12/699,761 | 2010-02-03 | ||
| US12/699,761 US8673860B2 (en) | 2009-02-03 | 2010-02-03 | Extended recombinant polypeptides and compositions comprising same |
| USPCT/US2010/023106 | 2010-02-03 | ||
| PCT/US2010/037849 WO2010144502A2 (en) | 2009-06-08 | 2010-06-08 | Growth hormone polypeptides and methods of making and using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015068675A Division JP2015124222A (ja) | 2009-06-08 | 2015-03-30 | 成長ホルモンポリペプチド並びにその作成及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012529296A JP2012529296A (ja) | 2012-11-22 |
| JP2012529296A5 true JP2012529296A5 (enExample) | 2013-08-15 |
| JP5805634B2 JP5805634B2 (ja) | 2015-11-04 |
Family
ID=43309446
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012515080A Expired - Fee Related JP5805634B2 (ja) | 2009-06-08 | 2010-06-08 | 成長ホルモンポリペプチド並びにその作成及び使用方法 |
| JP2015068675A Withdrawn JP2015124222A (ja) | 2009-06-08 | 2015-03-30 | 成長ホルモンポリペプチド並びにその作成及び使用方法 |
| JP2016151272A Withdrawn JP2016185171A (ja) | 2009-06-08 | 2016-08-01 | 成長ホルモンポリペプチド並びにその作成及び使用方法 |
| JP2017181582A Expired - Fee Related JP6543668B2 (ja) | 2009-06-08 | 2017-09-21 | 成長ホルモンポリペプチド並びにその作成及び使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015068675A Withdrawn JP2015124222A (ja) | 2009-06-08 | 2015-03-30 | 成長ホルモンポリペプチド並びにその作成及び使用方法 |
| JP2016151272A Withdrawn JP2016185171A (ja) | 2009-06-08 | 2016-08-01 | 成長ホルモンポリペプチド並びにその作成及び使用方法 |
| JP2017181582A Expired - Fee Related JP6543668B2 (ja) | 2009-06-08 | 2017-09-21 | 成長ホルモンポリペプチド並びにその作成及び使用方法 |
Country Status (26)
| Country | Link |
|---|---|
| EP (2) | EP3278813A1 (enExample) |
| JP (4) | JP5805634B2 (enExample) |
| KR (1) | KR101813727B1 (enExample) |
| CN (2) | CN106916229A (enExample) |
| AU (1) | AU2010258892B2 (enExample) |
| BR (1) | BRPI1010880A2 (enExample) |
| CA (1) | CA2764105A1 (enExample) |
| CL (1) | CL2011003121A1 (enExample) |
| DK (1) | DK2440241T3 (enExample) |
| EA (1) | EA030619B1 (enExample) |
| ES (1) | ES2643641T3 (enExample) |
| HK (1) | HK1250215A1 (enExample) |
| HR (1) | HRP20171644T1 (enExample) |
| HU (1) | HUE037249T2 (enExample) |
| IL (1) | IL216680A (enExample) |
| LT (1) | LT2440241T (enExample) |
| MX (2) | MX354555B (enExample) |
| NO (1) | NO2440241T3 (enExample) |
| NZ (2) | NZ621868A (enExample) |
| PE (1) | PE20121539A1 (enExample) |
| PL (1) | PL2440241T3 (enExample) |
| PT (1) | PT2440241T (enExample) |
| SG (2) | SG176726A1 (enExample) |
| SI (1) | SI2440241T1 (enExample) |
| WO (1) | WO2010144502A2 (enExample) |
| ZA (2) | ZA201200123B (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6263355A (ja) * | 1985-09-13 | 1987-03-20 | Hitachi Ltd | バツテリバツクアツプｒａｍのチエツク方法 |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| US20110046060A1 (en) | 2009-08-24 | 2011-02-24 | Amunix Operating, Inc., | Coagulation factor IX compositions and methods of making and using same |
| SI2393828T1 (sl) | 2009-02-03 | 2017-01-31 | Amunix Operating Inc. | Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo |
| JP5805634B2 (ja) * | 2009-06-08 | 2015-11-04 | アムニクス オペレーティング インコーポレイテッド | 成長ホルモンポリペプチド並びにその作成及び使用方法 |
| US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| AU2010258898B8 (en) | 2009-06-08 | 2015-02-05 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
| WO2011123830A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
| AU2011254564B2 (en) | 2010-05-21 | 2014-03-27 | Xl-Protein Gmbh | Biosynthetic proline/alanine random coil polypeptides and their uses |
| ES2724778T3 (es) | 2011-06-10 | 2019-09-16 | Bioverativ Therapeutics Inc | Compuestos procoagulantes y procedimientos de uso de los mismos |
| CN111499761A (zh) | 2012-01-12 | 2020-08-07 | 比奥贝拉蒂治疗公司 | 嵌合因子viii多肽及其用途 |
| NZ628014A (en) | 2012-02-15 | 2016-09-30 | Biogen Ma Inc | Recombinant factor viii proteins |
| CN111548418A (zh) | 2012-02-15 | 2020-08-18 | 比奥贝拉蒂治疗公司 | 因子viii组合物及其制备和使用方法 |
| CN104302408B (zh) | 2012-02-27 | 2016-12-14 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| DK2858664T3 (da) * | 2012-06-05 | 2019-07-08 | Amunix Pharmaceuticals Inc | Hgh-xten-fusionsprotein og anvendelse deraf i behandling af væksthormonmangel |
| US10202595B2 (en) | 2012-06-08 | 2019-02-12 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
| EP2858659B1 (en) | 2012-06-08 | 2019-12-25 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
| AU2013290173B2 (en) * | 2012-07-11 | 2018-02-15 | Bioverativ Therapeutics Inc. | Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof |
| DK2956477T4 (da) | 2013-02-15 | 2024-04-15 | Bioverativ Therapeutics Inc | Optimeret faktor viii-gen |
| EA037906B1 (ru) | 2013-03-15 | 2021-06-04 | Биовератив Терапьютикс Инк. | Препараты полипептида фактора ix |
| HK1223302A1 (zh) | 2013-06-28 | 2017-07-28 | Bioverativ Therapeutics Inc. | 具有xten的凝血酶可裂解连接子和其用途 |
| EP3043813B1 (en) | 2013-08-08 | 2021-01-13 | Bioverativ Therapeutics Inc. | Purification of chimeric fviii molecules |
| WO2015023894A1 (en) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| US10584147B2 (en) | 2013-11-08 | 2020-03-10 | Biovertiv Therapeutics Inc. | Procoagulant fusion compound |
| PH12016501323B1 (en) | 2014-01-10 | 2022-04-29 | Bioverativ Therapeutics Inc | Factor viii chimeric proteins and uses thereof |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| WO2016046301A1 (en) | 2014-09-26 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Stabilized adrenomedullin derivatives and use thereof |
| CN108064282A (zh) | 2014-10-14 | 2018-05-22 | 哈洛齐梅公司 | 腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法 |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| JP2018500049A (ja) * | 2014-11-11 | 2018-01-11 | アムニクス オペレーティング インコーポレイテッド | ターゲティングｘｔｅｎコンジュゲート組成物およびそれを作製する方法 |
| AU2016301303B2 (en) | 2015-08-03 | 2021-10-07 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| JP2019501961A (ja) * | 2015-12-03 | 2019-01-24 | ディーエヌエー エッセンス ゲーエムベーハーＤｎａ Ｅｓｓｅｎｃｅ Ｇｍｂｈ | 食品、飲料、化粧料、及び医薬の組成物中のオリゴヌクレオチド |
| KR20180118659A (ko) | 2016-02-01 | 2018-10-31 | 바이오버라티브 테라퓨틱스 인크. | 최적화된 viii 인자 유전자 |
| WO2018102743A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| CN110520149A (zh) | 2016-12-02 | 2019-11-29 | 比奥维拉迪维治疗股份有限公司 | 诱导对凝血因子的免疫耐受性的方法 |
| EP3576762A1 (en) | 2017-01-31 | 2019-12-11 | Bioverativ Therapeutics Inc. | Factor ix fusion proteins and methods of making and using same |
| TWI904068B (zh) | 2017-08-09 | 2025-11-11 | 美商生物化學醫療公司 | 核酸分子及其用途 |
| JP2021507706A (ja) | 2017-12-21 | 2021-02-25 | アムニクス ファーマシューティカルズ， インコーポレイテッド | 放出セグメントおよびそれを含む結合組成物 |
| SG11202007114VA (en) | 2018-02-01 | 2020-08-28 | Bioverativ Therapeutics Inc | Use of lentiviral vectors expressing factor viii |
| BR112020018709A2 (pt) | 2018-03-28 | 2021-01-05 | Bristol-Myers Squibb Company | Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso |
| JP7763589B2 (ja) | 2018-05-18 | 2025-11-04 | バイオベラティブ セラピューティクス インコーポレイテッド | 血友病ａを処置する方法 |
| US12226451B2 (en) | 2018-07-03 | 2025-02-18 | Bristol-Myers Squibb Company | FGF-21 formulations |
| WO2020033863A1 (en) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| KR20210111242A (ko) | 2018-10-29 | 2021-09-10 | 바이오젠 엠에이 인코포레이티드 | 혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체 |
| AU2019393880A1 (en) | 2018-12-06 | 2021-07-15 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor IX |
| WO2020254197A1 (en) | 2019-06-18 | 2020-12-24 | Bayer Aktiengesellschaft | Adrenomedullin-analogues for long-term stabilization and their use |
| TW202126284A (zh) | 2019-09-30 | 2021-07-16 | 美商百歐維拉提夫治療公司 | 慢病毒載體配製物 |
| JP7725466B2 (ja) | 2019-11-13 | 2025-08-19 | アムニクス ファーマシューティカルズ， インコーポレイテッド | バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法 |
| WO2021262963A1 (en) | 2020-06-24 | 2021-12-30 | Bioverativ Therapeutics Inc. | Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein |
| CA3182372A1 (en) | 2020-06-25 | 2021-12-30 | Amunix Pharmaceuticals, Inc. | Her-2 targeted bispecific compositions and methods for making and using the same |
| CA3229668A1 (en) | 2021-08-23 | 2023-03-02 | Bioverativ Therapeutics Inc. | Baculovirus expression system |
| KR20240049332A (ko) | 2021-08-23 | 2024-04-16 | 바이오버라티브 테라퓨틱스 인크. | 최적화된 인자 viii 유전자 |
| CN113880954B (zh) * | 2021-09-29 | 2024-05-14 | 江苏大学 | 一种重组人生长激素及其构建方法和应用 |
| EP4408874A1 (en) | 2021-09-30 | 2024-08-07 | Bioverativ Therapeutics Inc. | Nucleic acids encoding factor viii polypeptides with reduced immunogenicity |
| CN116554343B (zh) * | 2022-01-30 | 2024-07-12 | 领诺(上海)医药科技有限公司 | 一种长效重组人生长激素及其应用 |
| JP2026505405A (ja) | 2023-02-10 | 2026-02-13 | アムニクス ファーマシューティカルズ， インコーポレイテッド | 前立腺特異的膜抗原（ｐｓｍａ）を標的とする組成物、並びにそれを作製及び使用するための方法 |
| US20240400696A1 (en) | 2023-04-17 | 2024-12-05 | Amunix Pharmaceuticals, Inc. | Compositions targeting epidermal growth factor receptor and methods for making and using the same |
| WO2025122957A1 (en) | 2023-12-08 | 2025-06-12 | Amunix Pharmaceuticals, Inc. | Protease activatable cytokines and methods for making and using the same |
| WO2026024863A2 (en) | 2024-07-24 | 2026-01-29 | Amunix Pharmaceuticals, Inc. | Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3992518A (en) | 1974-10-24 | 1976-11-16 | G. D. Searle & Co. | Method for making a microsealed delivery device |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4284444A (en) | 1977-08-01 | 1981-08-18 | Herculite Protective Fabrics Corporation | Activated polymer materials and process for making same |
| US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US4898830A (en) | 1979-07-05 | 1990-02-06 | Genentech, Inc. | Human growth hormone DNA |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US4398908A (en) | 1980-11-28 | 1983-08-16 | Siposs George G | Insulin delivery system |
| US4435173A (en) | 1982-03-05 | 1984-03-06 | Delta Medical Industries | Variable rate syringe pump for insulin delivery |
| US4943529A (en) | 1982-05-19 | 1990-07-24 | Gist-Brocades Nv | Kluyveromyces as a host strain |
| AU3145184A (en) | 1983-08-16 | 1985-02-21 | Zymogenetics Inc. | High expression of foreign genes in schizosaccharomyces pombe |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US5231112A (en) | 1984-04-12 | 1993-07-27 | The Liposome Company, Inc. | Compositions containing tris salt of cholesterol hemisuccinate and antifungal |
| ATE59302T1 (de) | 1984-07-24 | 1991-01-15 | Key Pharma | Klebende schicht zur transdermalen freigabe. |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4684479A (en) | 1985-08-14 | 1987-08-04 | Arrigo Joseph S D | Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US6759057B1 (en) | 1986-06-12 | 2004-07-06 | The Liposome Company, Inc. | Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs |
| IE60901B1 (en) | 1986-08-21 | 1994-08-24 | Vestar Inc | Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics |
| US4933185A (en) | 1986-09-24 | 1990-06-12 | Massachusetts Institute Of Technology | System for controlled release of biologically active compounds |
| US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
| US4976696A (en) | 1987-08-10 | 1990-12-11 | Becton, Dickinson And Company | Syringe pump and the like for delivering medication |
| US4861800A (en) | 1987-08-18 | 1989-08-29 | Buyske Donald A | Method for administering the drug deprenyl so as to minimize the danger of side effects |
| AU598958B2 (en) | 1987-11-12 | 1990-07-05 | Vestar, Inc. | Improved amphotericin b liposome preparation |
| GB8807504D0 (en) | 1988-03-29 | 1988-05-05 | Sandoz Ltd | Improvements in/relating to organic compounds |
| JP2717808B2 (ja) | 1988-08-10 | 1998-02-25 | テルモ株式会社 | シリンジポンプ |
| US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
| DE68927344T2 (de) | 1989-04-28 | 1997-02-20 | Rhein Biotech Proz & Prod Gmbh | Hefezellen der Gattung-Schwanniomyces |
| US5017378A (en) | 1989-05-01 | 1991-05-21 | The University Of Virginia Alumni Patents Foundation | Intraorgan injection of biologically active compounds contained in slow-release microcapsules or microspheres |
| US5298022A (en) | 1989-05-29 | 1994-03-29 | Amplifon Spa | Wearable artificial pancreas |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| FR2649120B1 (fr) | 1989-06-30 | 1994-01-28 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
| US5492534A (en) | 1990-04-02 | 1996-02-20 | Pharmetrix Corporation | Controlled release portable pump |
| US5318540A (en) | 1990-04-02 | 1994-06-07 | Pharmetrix Corporation | Controlled release infusion device |
| US5176502A (en) | 1990-04-25 | 1993-01-05 | Becton, Dickinson And Company | Syringe pump and the like for delivering medication |
| US5215680A (en) | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| US5573776A (en) | 1992-12-02 | 1996-11-12 | Alza Corporation | Oral osmotic device with hydrogel driving member |
| US5660848A (en) | 1994-11-02 | 1997-08-26 | The Population Council, Center For Biomedical Research | Subdermally implantable device |
| GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| PT929293E (pt) | 1996-08-23 | 2004-03-31 | Sequus Pharm Inc | Lipossomas contendo um composto de cisplatina |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| JP2001503396A (ja) | 1996-10-11 | 2001-03-13 | アルザ コーポレイション | 治療用リポソーム組成物および方法 |
| HUP0000522A3 (en) | 1996-10-15 | 2000-10-30 | Transave Inc Monmouth Junction | N-acyl phoshpatidylethanolamine-mediated liposomal drug delivery |
| US6361796B1 (en) | 1996-10-25 | 2002-03-26 | Shire Laboratories, Inc. | Soluble form osmotic dose delivery system |
| JP4863534B2 (ja) | 1996-10-25 | 2012-01-25 | スパーナス ファーマシューティカルズ インコーポレイテッド | 可溶形態浸透用量送達システム |
| DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
| DE19747261A1 (de) | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
| EP1563866B1 (en) | 1998-02-05 | 2007-10-03 | Biosense Webster, Inc. | Intracardiac drug delivery |
| US6406632B1 (en) | 1998-04-03 | 2002-06-18 | Symyx Technologies, Inc. | Rapid characterization of polymers |
| GB9815157D0 (en) | 1998-07-13 | 1998-09-09 | Metron Designs Ltd | High resolution pulse width setting from relatively low frequency clocks |
| US6713086B2 (en) | 1998-12-18 | 2004-03-30 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| US6715485B1 (en) | 1999-03-03 | 2004-04-06 | Optinose As | Nasal delivery device |
| US6183770B1 (en) | 1999-04-15 | 2001-02-06 | Acutek International | Carrier patch for the delivery of agents to the skin |
| US6743211B1 (en) | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
| US6352721B1 (en) | 2000-01-14 | 2002-03-05 | Osmotica Corp. | Combined diffusion/osmotic pumping drug delivery system |
| US20030228309A1 (en) | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
| IN190699B (enExample) | 2001-02-02 | 2003-08-16 | Sun Pharmaceutical Ind Ltd | |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| WO2002087621A1 (en) | 2001-04-30 | 2002-11-07 | Shire Laboratories Inc. | Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers |
| US6838093B2 (en) | 2001-06-01 | 2005-01-04 | Shire Laboratories, Inc. | System for osmotic delivery of pharmaceutically active agents |
| KR100407467B1 (ko) | 2001-07-12 | 2003-11-28 | 최수봉 | 리모컨 방식의 인슐린 자동주사기 |
| DK1499888T3 (da) * | 2002-04-29 | 2010-10-25 | Euro Celtique Sa | Peptider med indskrænket konformation, der binder sig til ORL-1-receptor |
| US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
| US7294513B2 (en) | 2002-07-24 | 2007-11-13 | Wyatt Technology Corporation | Method and apparatus for characterizing solutions of small particles |
| SE0300959D0 (sv) * | 2002-12-19 | 2003-04-02 | Pharmacia Ab | Methods for predicting therapeutic response to agents acting on the growth hormone receptor |
| US20090099031A1 (en) | 2005-09-27 | 2009-04-16 | Stemmer Willem P | Genetic package and uses thereof |
| EP2863222A1 (en) * | 2006-03-06 | 2015-04-22 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
| KR101524880B1 (ko) * | 2006-08-31 | 2015-06-01 | 노파르티스 아게 | Ｈｇｈ를 포함하는 경구 전달용 제약 조성물 |
| HRP20110368T1 (hr) * | 2007-06-21 | 2011-06-30 | Technische Universitt Mnchen | Biološki aktivni proteini s povećanom stabilnošću in vivo i/ili in vitro |
| CN103298935A (zh) | 2007-08-15 | 2013-09-11 | 阿穆尼克斯公司 | 用于改善生物活性多肽性能的组合物和方法 |
| SI2393828T1 (sl) * | 2009-02-03 | 2017-01-31 | Amunix Operating Inc. | Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo |
| JP5805634B2 (ja) * | 2009-06-08 | 2015-11-04 | アムニクス オペレーティング インコーポレイテッド | 成長ホルモンポリペプチド並びにその作成及び使用方法 |
-
2010
- 2010-06-08 JP JP2012515080A patent/JP5805634B2/ja not_active Expired - Fee Related
- 2010-06-08 MX MX2015002843A patent/MX354555B/es unknown
- 2010-06-08 PT PT107867251T patent/PT2440241T/pt unknown
- 2010-06-08 EA EA201190326A patent/EA030619B1/ru not_active IP Right Cessation
- 2010-06-08 DK DK10786725.1T patent/DK2440241T3/en active
- 2010-06-08 KR KR1020127000327A patent/KR101813727B1/ko not_active Expired - Fee Related
- 2010-06-08 NO NO10786725A patent/NO2440241T3/no unknown
- 2010-06-08 ES ES10786725.1T patent/ES2643641T3/es active Active
- 2010-06-08 SI SI201031565T patent/SI2440241T1/sl unknown
- 2010-06-08 EP EP17175282.7A patent/EP3278813A1/en not_active Withdrawn
- 2010-06-08 NZ NZ621868A patent/NZ621868A/en not_active IP Right Cessation
- 2010-06-08 HU HUE10786725A patent/HUE037249T2/hu unknown
- 2010-06-08 SG SG2011090735A patent/SG176726A1/en unknown
- 2010-06-08 SG SG10201704777RA patent/SG10201704777RA/en unknown
- 2010-06-08 NZ NZ596787A patent/NZ596787A/en not_active IP Right Cessation
- 2010-06-08 BR BRPI1010880A patent/BRPI1010880A2/pt not_active Application Discontinuation
- 2010-06-08 CN CN201710121061.7A patent/CN106916229A/zh not_active Withdrawn
- 2010-06-08 WO PCT/US2010/037849 patent/WO2010144502A2/en not_active Ceased
- 2010-06-08 CA CA2764105A patent/CA2764105A1/en not_active Abandoned
- 2010-06-08 MX MX2011013183A patent/MX2011013183A/es active IP Right Grant
- 2010-06-08 AU AU2010258892A patent/AU2010258892B2/en not_active Ceased
- 2010-06-08 CN CN201080035159.7A patent/CN103140236B/zh not_active Expired - Fee Related
- 2010-06-08 HR HRP20171644TT patent/HRP20171644T1/hr unknown
- 2010-06-08 EP EP10786725.1A patent/EP2440241B1/en active Active
- 2010-06-08 PE PE2011002057A patent/PE20121539A1/es active IP Right Grant
- 2010-06-08 PL PL10786725T patent/PL2440241T3/pl unknown
- 2010-06-08 LT LTEP10786725.1T patent/LT2440241T/lt unknown
-
2011
- 2011-11-29 IL IL216680A patent/IL216680A/en not_active IP Right Cessation
- 2011-12-07 CL CL2011003121A patent/CL2011003121A1/es unknown
-
2012
- 2012-01-06 ZA ZA2012/00123A patent/ZA201200123B/en unknown
-
2014
- 2014-08-04 ZA ZA2014/05743A patent/ZA201405743B/en unknown
-
2015
- 2015-03-30 JP JP2015068675A patent/JP2015124222A/ja not_active Withdrawn
-
2016
- 2016-08-01 JP JP2016151272A patent/JP2016185171A/ja not_active Withdrawn
-
2017
- 2017-09-21 JP JP2017181582A patent/JP6543668B2/ja not_active Expired - Fee Related
-
2018
- 2018-07-26 HK HK18109676.2A patent/HK1250215A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012529296A5 (enExample) | ||
| KR101708730B1 (ko) | 장기 작용 폴리펩티드 및 그의 생산 및 투여 방법 | |
| ES2983610T3 (es) | Hormona del crecimiento de acción prolongada y métodos para producir la misma | |
| KR101350251B1 (ko) | 목적 펩타이드의 혈장내 반감기 연장 작용을 가진 펩타이드 | |
| US8999670B2 (en) | Long-acting polypeptides and methods of producing same | |
| JP2012529297A5 (enExample) | ||
| US20130157953A1 (en) | Treatment of cardiac conditions | |
| HRP20171644T1 (hr) | Polipeptidi hormona rasta kao i postupci za njihovu proizvodnju i uporabu | |
| JP2016511752A5 (enExample) | ||
| WO2011020319A1 (zh) | 调节血糖血脂的融合蛋白及其制备方法和应用 | |
| JP2010518079A5 (enExample) | ||
| JP2017529059A5 (enExample) | ||
| JP2016512213A5 (enExample) | ||
| CN105008395B (zh) | 长效单链胰岛素类似物 | |
| JP2009525052A5 (enExample) | ||
| JP2016518351A5 (enExample) | ||
| CN103408669A (zh) | Glp-1类似物融合蛋白，及其制备方法和用途 | |
| CN109689086A (zh) | 具有延长的血清半衰期的融合蛋白 | |
| WO2011031477A2 (en) | Nucleolin-binding peptides, nucleolin-binding lytic peptides, fusion constructs and methods of making and using same | |
| JP7445695B2 (ja) | 長期活性型ポリペプチドならびに当該ポリペプチドの製造方法および投与方法 | |
| JP2009510999A (ja) | キメラ治療剤 | |
| Mak et al. | Preparation of potent leptin receptor antagonists and their therapeutic use in mouse models of uremic cachexia and kidney fibrosis | |
| CN106432511A (zh) | GLP‑1类似物‑Fc融合蛋白及其制备方法和用途 | |
| JP2021505656A (ja) | グルカゴン様ペプチド | |
| WO2015090234A1 (en) | Improving pharmacokinetic profile for angiopoietin-2 inhibiting polypeptide or thymalfasin |